


Accepted Manuscript

Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung

Edward M. Wolin, MD



PII: S0012-3692(16)50383-3

DOI: [10.1016/j.chest.2016.06.018](https://doi.org/10.1016/j.chest.2016.06.018)

Reference: CHEST 530

To appear in: *CHEST*

Received Date: 3 March 2016

Revised Date: 10 June 2016

Accepted Date: 23 June 2016

Please cite this article as: Wolin EM, Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung, *CHEST* (2016), doi: 10.1016/j.chest.2016.06.018.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract word count: 249 words

Text word count: 2291 words

1 **Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-**
2 **Differentiated Neuroendocrine Tumors of the Lung**

3 *Edward M. Wolin, MD*

4

5 **RUNNING TITLE:** Advances in Lung Neuroendocrine Tumors

6

7 **ABBREVIATIONS:** AC = atypical carcinoids; DCR = disease control rate; ENETS; European
8 Neuroendocrine Tumor Society; GI = gastrointestinal; LAR = long-acting repeatable; LCNEC =
9 large cell neuroendocrine carcinoma; NCCN = National Comprehensive Cancer Network; NET
10 = neuroendocrine tumors; PFS = progression-free survival; PRRT = peptide receptor
11 radionuclide therapy; SCLC = small cell lung carcinoma; SSSTR = somatostatin receptor; TC =
12 typical carcinoids; WHO = World Health Organization

13

14 **AFFILIATIONS:** From Montefiore M-E Center for Cancer Care, Bronx, NY.

15

16 **CONFLICT OF INTEREST:** E. W. has received consulting fees from Novartis, Ipsen, Celgene,
17 and Advanced Accelerator Applications.

18

19 **FUNDING INFORMATION:** Financial support for editorial assistance was provided by
20 Novartis Pharmaceuticals, Inc., in compliance with international guidelines on Good Publication
21 Practice.

22

Download English Version:

<https://daneshyari.com/en/article/5600936>

Download Persian Version:

<https://daneshyari.com/article/5600936>

[Daneshyari.com](https://daneshyari.com)